Video

Q&A with Mitchell Smith: The Merits of Ten Year Followup

Author(s):

Mitchell Smith, MD, Cleveland Clinic shared highlights of his team's posters and discussed the progression of immunotherapies at the 57th American Society of Hematology Annual Meeting.

Mitchell Smith, MD, Cleveland Clinic shared highlights of his team's posters and discussed the progression of immunotherapies at the 57th American Society of Hematology Annual Meeting.

According to Smith, "While response rates aren't as high as we like, and they're not durable in everyone, you can see on the horizon advances in the cell technology and in patient selection."

Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.